Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III recombinant herpes zoster vaccine (CHO) efficacy and safety trial in adults ≥40 years
ChiCTR2300076253Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial Centre for Disease Prevention and Control
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant herpes zoster vaccine (CHO) in herpes zoster (HZ) (2 arms), sponsored by Jiangsu Provincial Centre for Disease Prevention and Control. Primary endpoint: Number of herpes zoster cases. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
recombinant herpes zoster vaccine (CHO)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on ChiCTR2300076253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076253.